Dynavax (DVAX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
February 23, 2023 4:05 PM EST2022 total revenue of $723 million, up 64% from $439 million in 2021HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021CpG 1018® adjuvant vaccine net product revenue of $588 million2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-47%Increased strength of financial position with year-end cash and investments of $624 millionConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ --... More
